Why the study?
Pregnancy outcome data after ulipristal acetate exposure are very limited, and well-grounded risk assessments are needed in cases of emergency contraception failure or unplanned pregnancy during myoma treatment.
Does ulipristal acetate exposure during early pregnancy increase the risk of birth defects, spontaneous abortion, or elective termination in pregnant women?
Does ulipristal acetate exposure during early pregnancy increase the risk of birth defects, spontaneous abortion, or elective termination in pregnant women?
Exposure to ulipristal acetate during early pregnancy did not show an increased risk for birth defects or spontaneous abortions in a small prospective cohort, though a retrospective case of Beckwith-Wiedemann syndrome warrants further study.
Answers are grounded in this paper and cite their sources.
Supports UPA safety in early pregnancy; hypothesis-generating and requires prospective confirmation before practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wagner et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: